These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37025256)

  • 1. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA.
    Chen X; Hou X; Bai D; Lane R; Zhang C; Canuso C; Wang G; Fu DJ
    Neuropsychiatr Dis Treat; 2023; 19():693-707. PubMed ID: 37025256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
    BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
    Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J
    CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
    J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
    Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S
    Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
    Ionescu DF; Fu DJ; Qiu X; Lane R; Lim P; Kasper S; Hough D; Drevets WC; Manji H; Canuso CM
    Int J Neuropsychopharmacol; 2021 Jan; 24(1):22-31. PubMed ID: 32861217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
    Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
    Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC
    Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
    Doty RL; Popova V; Wylie C; Fedgchin M; Daly E; Janik A; Ochs-Ross R; Lane R; Lim P; Cooper K; Melkote R; Jamieson C; Singh J; Drevets WC
    CNS Drugs; 2021 Jul; 35(7):781-794. PubMed ID: 34235612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
    Daly EJ; Turkoz I; Salvadore G; Fedgchin M; Ionescu DF; Starr HL; Borentain S; Trivedi MH; Thase ME; Singh JB
    Depress Anxiety; 2021 Nov; 38(11):1120-1130. PubMed ID: 34293233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability.
    Jha MK; Williamson DJ; Magharehabed G; Turkoz I; Daly EJ; Trivedi MH
    J Affect Disord; 2023 Jan; 321():153-160. PubMed ID: 36273682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
    Singh JB; Fedgchin M; Daly E; Xi L; Melman C; De Bruecker G; Tadic A; Sienaert P; Wiegand F; Manji H; Drevets WC; Van Nueten L
    Biol Psychiatry; 2016 Sep; 80(6):424-431. PubMed ID: 26707087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials.
    Diekamp B; Borentain S; Fu DJ; Murray R; Heerlein K; Zhang Q; Schüle C; Mathews M
    Neuropsychiatr Dis Treat; 2021; 17():2347-2357. PubMed ID: 34290505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
    Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
    CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.